Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

NCT01459081 Phase 3 COMPLETED

The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.

Details

Lead sponsor	Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	298
Start date	2011-10
Completion	2012-12

Conditions

• Influenza A Virus Infection
• Influenza B Virus Infection

Interventions

• Zanamivir
• Placebo

Primary outcomes

• Time to alleviation of clinically important symptoms — up to 21 days

Countries

China